Initiator Pharma A/S (STO: INIT)

Market Cap	382.46M
Revenue (ttm)	n/a
Net Income (ttm)	-16.16M
Shares Out	56.24M
EPS (ttm)	-0.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	147,130
Open	7.10
Previous Close	6.90
Day's Range	6.40 - 7.15
52-Week Range	6.30 - 11.75
Beta	0.75
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 29, 2024

About Initiator Pharma

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes IPED2015, a drug candidate which is in clinical phase 2a for the treatment of organic erectile dysfunction; IP2018, a monoamine reuptake inhibitor completed Phase IIa for the treatment of psychogenic erectile dysfunction primarily targeting the serotonin followed by the dopamine system; and IPTN2021, a Phase 1 clinical drug program targeting an orphan drug indic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 3
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: INIT

Financial Performance

Financial numbers in DKK